J
James F. Bishop
Researcher at Cancer Institute of New South Wales
Publications - 115
Citations - 3259
James F. Bishop is an academic researcher from Cancer Institute of New South Wales. The author has contributed to research in topics: Chemotherapy & Cancer. The author has an hindex of 27, co-authored 114 publications receiving 3120 citations. Previous affiliations of James F. Bishop include Royal Prince Alfred Hospital & Australian Department of Health and Ageing.
Papers
More filters
Journal ArticleDOI
Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.
Alan S. Coates,Val Gebski,James F. Bishop,Peter N. Jeal,R. L. Woods,Raymond Snyder,Martin H.N. Tattersall,M. J. Byrne,V J Harvey,Grantley Gill,John Simpson,Roslyn M. Drummond,Judy Browne,Rodney van Cooten,John F. Forbes +14 more
TL;DR: Continuous chemotherapy is better than intermittent chemotherapy for advanced breast cancer, as tested, and changes in the quality of life were independent prognostic factors in proportional-hazards models of subsequent survival.
Journal ArticleDOI
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.
Audrey Mauguen,Cécile Le Péchoux,Michele I. Saunders,Steven E. Schild,Andrew T. Turrisi,Michael Baumann,William T. Sause,David Ball,Chandra P. Belani,James A. Bonner,A. Zajusz,Suzanne E. Dahlberg,Matthew Nankivell,Sumithra J. Mandrekar,Rebecca Paulus,Katarzyna Behrendt,Rainer Koch,James F. Bishop,Stanley Dische,Rodrigo Arriagada,Rodrigo Arriagada,Dirk De Ruysscher,Jean Pierre Pignon +22 more
TL;DR: Patients with nonmetastatic NSCLC derived a significant OS benefit from accelerated or hyperfractionated radiotherapy; a similar but nonsignificant trend was observed for SCLC; as expected, there was increased acute esophageal toxicity.
Journal ArticleDOI
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.
James F. Bishop,J. Dewar,G. C. Toner,Jennifer A. Smith,Martin H.N. Tattersall,Ian N. Olver,Stephen P. Ackland,Ian Kennedy,David Goldstein,Howard Gurney,Euan Walpole,John A. Levi,Jennifer Stephenson,Renzo M. Canetta +13 more
TL;DR: Initial paclitaxel was associated with significantly less myelosuppression and fewer infections, with longer survival and similar quality of life and control of metastatic breast cancer compared with CMFP.
Journal ArticleDOI
Australia's winter with the 2009 pandemic influenza A (H1N1) virus.
TL;DR: Key lessons from Australia's experience with the spread of H1N1 suggest that important elements of a response were a national coordination of efforts and the use and modification of a national pandemic plan framework.
Journal ArticleDOI
Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
Lorraine K. Webster,Martha E. Linsenmeyer,Michael Millward,Carmel G. Morton,James F. Bishop,David M. Woodcock +5 more
TL;DR: The efficacy of paclitaxel against some tumors may be aided by its administration in a vehicle solution containing Cremophor in quantities that reach concentrations in the plasma sufficient to reverse multidrug resistance of neoplastic cells.